On October 7, BioAtla, LLC, announced a new Fully Human Antibody Platform with full-length antibodies and over 10^9 members expressed in mammalian cells. This proprietary, expanded and validated high diversity HuAb library is immediately available to BioAtla’s client partners.
The platform maintains the same screening timeframes of traditional methods while capitalizing on one of the most proven and safe glycosylating systems, reducing the potential for negative immunogenicity.
For more information, visit our GigaMab™ Fully Human Library informational page.
About BioAtla, LLC
BioAtla, LLC (bioatla.com) is a global, biology outsourcing services provider based in San Diego, CA with significant research operations in San Diego, New York, Beijing and expanding in 2011. We are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for our client partners.
Our exclusive manufacturing partnership with China-based BioDuro, a PPD company, and our intellectual property partnership with Capia IP translates our industry know-how and thought leadership into tangible, ownable results for our clients.